Provided by Tiger Trade Technology Pte. Ltd.

Vertex, Inc.

12.79
+0.01500.12%
Volume:142.52K
Turnover:1.83M
Market Cap:2.07B
PE:580.13
High:12.97
Open:12.77
Low:12.75
Close:12.77
52wk High:26.54
52wk Low:10.21
Shares:162.00M
Float Shares:70.89M
Volume Ratio:0.59
T/O Rate:0.20%
Dividend:- -
Dividend Rate:- -
EPS(TTM):0.0220
EPS(LYR):0.0444
ROE:1.46%
ROA:0.65%
PB:8.59
PE(LYR):287.98

Loading ...

Earning Preview: Vertex, Inc. this quarter’s revenue is expected to increase by 9.59%, and institutional views are positive

Earnings Agent
·
Jul 28

Venu Holding Secures $20 Million Bridge Loan Facility with Ryan LLC for Texas Venue Project

Reuters
·
Jul 23

Vertex Minerals appoints independent expert after multiple ASX Listing Rule breaches

TIPRANKS
·
Jul 23

Vertex Pharmaceuticals Inc. Stock Underperforms Wednesday When Compared to Competitors

Dow Jones
·
Jul 23

What the $10B Crinetics Deal & $2.9B Soleno Acquisition Might Say About Palatin’s Rare-Obesity Opportunity

TIPRANKS
·
Jul 22

Vertex Facing Uncertain Growth Path Amid AI Fears, Morgan Stanley Says

MT Newswires Live
·
Jul 21

VENU Secures Bridge Loan Financing Facility with Ryan, LLC to Advance National Expansion

Reuters
·
Jul 21

Venu Holding Secures $20 Million Bridge Loan Facility with Ryan LLC

Reuters
·
Jul 21

Vertex Inc. : Morgan Stanley Cuts to Equal-weight from Overweight

THOMSON REUTERS
·
Jul 21

Morgan Stanley Downgrades Vertex to Equalweight From Overweight, Cuts Price Target to $15 From $19

MT Newswires Live
·
Jul 21

Vertex Pharmaceuticals Inc. Stock Underperforms Monday When Compared to Competitors

Dow Jones
·
Jul 21

Goldman Sachs Adjusts Price Target on Vertex Pharmaceuticals to $652 From $641, Maintains Buy Rating

MT Newswires Live
·
Jul 20

Vertex Pharmaceuticals Inc. Stock Underperforms Thursday When Compared to Competitors Despite Daily Gains

Dow Jones
·
Jul 17

Vertex’s VX-581 Dose Escalation Trial: A Fresh Signal on Cystic Fibrosis Pipeline Strength

TIPRANKS
·
Jul 17

Vertex Pharmaceuticals Currently Down Seven Consecutive Days, on Pace for Longest Losing Streak Since August 2021

Dow Jones
·
Jul 15

After Crinetics’ $10 Billion Deal, Could Entera Bio Be the Next Category-Defining Oral Peptide Story?

TIPRANKS
·
Jul 15

Crinetics Pharmaceuticals (CRNX) Looks Fully Valued As Vertex Agrees $85 Per Share Deal

Simply Wall St.
·
Jul 15

Vertex to Report Q2 2026 Results After Market Close, Host Conference Call

Reuters
·
Jul 15

Vertex Minerals lifts gold sales and advances mechanised mining at Reward

TIPRANKS
·
Jul 14

Vertex Pharmaceuticals Inc. Stock Underperforms Monday When Compared to Competitors

Dow Jones
·
Jul 14